SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 2,566.06 |
| Enterprise Value ($M) | 2,521.25 |
| Book Value ($M) | 488.88 |
| Book Value / Share | 5.16 |
| Price / Book | 5.25 |
| NCAV ($M) | 477.03 |
| NCAV / Share | 5.04 |
| Price / NCAV | 5.38 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.25 |
| Return on Assets (ROA) | -0.37 |
| Return on Equity (ROE) | -0.39 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 26.35 |
| Current Ratio | 26.35 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 499.44 |
| Assets | 511.28 |
| Liabilities | 22.41 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Perceptive Advisors Llc | |||
| 13G | Janus Henderson Group Plc | |||
| 13G | Paradigm Biocapital Advisors LP | |||
| 13G | Baker Bros. Advisors Lp | 6.20 | ||
| 13G/A | EcoR1 Capital, LLC | 1.30 | -64.21 | |
| 13G/A | Flynn James E | 1.90 | -60.23 | |
| 13G/A | Viking Global Investors Lp | 1.60 | -75.95 | |
| 13D/A | Orbimed Advisors Llc | 15.60 | 0.00 | |
| 13G/A | Fmr Llc | 0.70 | -86.34 | |
| 13G | BlackRock, Inc. | 6.80 | 0.00 | |
| 13D/A | Novo Holdings A/S | 5.90 | -12.52 | |
| 13G/A | Deep Track Capital, LP | 4.00 | -24.81 | |
| 13G | Ra Capital Management, L.p. | 9.60 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 292,132 | 825,335 | 35.40 | |
| 595,638 | 1,498,844 | 39.74 | |
| 271,019 | 718,888 | 37.70 | |
| 382,781 | 1,013,142 | 37.78 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ELVN – Enliven Therapeutics, Inc. | ENTA – Enanta Pharmaceuticals, Inc. |
| ERAS – Erasca, Inc. | EXEL – Exelixis, Inc. |
| FDMT – 4D Molecular Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io